Advisory Alpha LLC Has $1.30 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Advisory Alpha LLC decreased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 58.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,576 shares of the company's stock after selling 2,175 shares during the period. Advisory Alpha LLC's holdings in Eli Lilly and Company were worth $1,302,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $43,000. FPC Investment Advisory Inc. raised its position in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after acquiring an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $48,000. Compass Financial Services Inc acquired a new position in Eli Lilly and Company during the fourth quarter worth about $50,000. Finally, Fiduciary Advisors Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $58,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of LLY traded up $1.72 during trading hours on Tuesday, hitting $748.84. The stock had a trading volume of 1,463,713 shares, compared to its average volume of 3,995,042. The company's fifty day moving average is $775.24 and its two-hundred day moving average is $799.98. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The stock has a market capitalization of $709.70 billion, a price-to-earnings ratio of 63.95, a P/E/G ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the company posted $2.58 EPS. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on LLY shares. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.